beilupharma @beilupharma - Tumblr Blog

Posts

As one of the best anti-anxiety drugs, Jiuweizhenxin Granules is a modern Chinese patent medicine independently developed by Beilu Pharma for the treatment of generalized anxiety disorder (GAD). It is a unique anti-GAD Chinese medicine approved by NMPA. The clinical efficacy of Jiuweizhenxin Granules in treating GAD is equivalent to that of Paroxetine tablets, but the adverse reactions of Jiuweizhenxin Granules are significantly lower than that of Paroxetine. Clinical research results show that taking Jiuweizhenxin Granules alone for 6 weeks can significantly improve the anxiety symptoms of patients and improve the quality of life with continuous use. Features Of Traditional Chinese Medicine-Jiuweizhenxin Granules Anti Anxiety Traditional Chinese Medicine Product name: Jiuweizhenxin Granules Ingredients: Ginseng(rhizome-removed), Wild jujube seed, Schisandra Chinensis, Poria cocos, polygala, rhizoma corydalis, Radix Asparagi, Cooked rehmannia root, cinnamon Specification: 6g/ bag Indication: Nourishing heart and tonifying spleen: the product is intended for generalized anxiety disorder, syndrome of deficiency of both heart and spleen, symptoms of unrelieved thoughtfulness and excessive worries, insomnia, dreaminess and palpitations. Benefiting vital energy and soothing the nerves: small and wiry pulse or deep thready pulse, sallow complexion, pale tongue with thin white coating, dizziness, sweating, frequent sighs, loss of appetite, fatigue weariness. Dosage and Administration: Administered with warm water, 1 bag each time, three times a day. Adverse Reactions: Occasionally dry mouth, hazy vision, increased constipation, nausea and vomiting, diarrhoea, inappetence or anorexia, abdominal distension, bitter mouth, gastric pain, somnolence, agrypnia, tremor, headache, wooziness, lipothymia, electrocardiogram abnormal, palpitations, tachycardia, ALT increased, white blood cells decreased, and menstrual disorders. Shelf life: 36 months The Effect of Jiuweizhenxin Granules Jiuweizhenxin Granules is a modern Chinese patent medicine approved by NMPA to treat anxiety disorders. The ingredients of Jiuweizhenxin Granules are Ginseng(rhigome-removed), Wild jujube seed, Schisandra Chinensis, Poria cocos, polygala, rhizoma corydalis, Radix Asparagi, Cooked Rehmannia root, cinnamon. The anti-anxiety effect is definite, especially for physical anxiety such as diarrhoea, headache, dizziness, and insomnia. It has a unique overall regulating effect. As one of the effective anti-anxiety drugs on the market, Jiuweizhenxin Granules can significantly improve anxiety and depression symptoms. If combined medication can significantly improve depression symptoms compared with the single medication group, the combination of Jiuweizhenxin Granules and duloxetine can significantly improve the clinical efficacy. Not only that, Jiuweizhenxin Granules can significantly improve the symptoms of insomnia in patients with insomnia. After taking Jiuweizhenxin Granules for 4 weeks, the time to fall asleep, sleep time, sleep quality, daytime dysfunction and total sleep score is better than the treatment before 【Note】Use with caution in patients with abnormal cardiac and liver functions and leukopenia.

#anti #anxiety #traditional #Chinese #medicine

CAS No.: 35453-19-1 Molecular formula: C8H4I3NO4 Molecular weight: 558.84 Quality standard: CP, USP Content (HPLC): ≥99.0% Packing: 25KG, 50KG/drum Storage: Protected from light, sealed tightly.

#35453

Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional ionic Contrast Media, Iohexol Injection has an excellent molecular structure and it can greatly improve user safety and significantly reduce adverse reactions. The iodinated contrast agent has excellent clinical feedback and good imaging results. In 1998, Iohexol Injection was launched as Beilu's 1st iodinated Contrast Media. Product name: Iohexol Injection Generic name: Iohexol Injection Type: Injectable Contrast Media for CT/X-ray Ingredients: Iohexol Specification: (1) 20 ml: 6 gI (2) 50 ml: 15 gI (3) 75 ml: 22.5 gI (4) 100 ml: 30 gI (5) 20 ml: 7 gI (6) 50 ml: 17.5 gI (7) 100 ml: 35 gI Administration: For injection or oral use of iodinated contrast Adverse reactions: See the details from the package insert Shelf life: 36 months.

#iohexol #package #insert

Iodixanol Injection is a CT/X-ray Contrast Media that is isotonic with plasma. It has excellent cardiac safety and renal safety, which is most comfortable to use, especially suitable for high risk patients. Product name: Iodixanol Injection Generic name: Iodixanol Injection Type: Injectable Contrast media for CT/X-ray Ingredients: Iodixanol Specification: (1)100ml-27 gl (2)50ml-16 gl (3)100ml-32 gl Administration: For Intravascular use only Adverse reactions: See the details from the package insert Shelf life: 24 months.

#visipaque #package #insert

Glimepiride Tablets is a sulfonylurea hypoglycemic drug that can be used in combination with insulin. In 2001, Glimepiride tablets (Dibei), as the first hypoglycemic product of Beilu Pharma, was first listed in China and belongs to the second class of national new drugs. Product name: Glimepiride Tablets Specifications: glimepiride 1 mg×30 tablets；glimepiride 2 mg×15 tablets；glimepiride 2mg×30 tablets Characteristics: White tablet Indications : As one of the oral antidiabetic drugs produced by Beilu Pharma, our glimepiride tablets are only suitable for type 2 diabetes that cannot fully control blood sugar through diet control, exercise therapy and weight loss. Glimepiride tablets are not suitable for type 1 diabetes (for example, the treatment of diabetic patients with a history of ketoacidosis), diabetic ketoacidosis or Treatment of pre-diabetic coma or coma. Usage and Dosage: Please refer to the package insert Adverse reactions, Contraindications, Precautions: Please refer to the package insert. Storage: Shade, seal, and keep in a dry place. Packaging: Aluminum plastic packaging, 15 pills/plate, 1 plate/box; 15 pills/plate, 2 plates/box. Shelf life: 24 months Advantages of Glimepiride Tablets Double effect directly hit the hypoglycemic core Double effect: Glimepiride tablets can promote insulin secretion and improve insulin resistance. At the same time, it can improve the two major pathophysiological abnormalities of insulin secretion and insulin resistance in patients with type 2 diabetes. Efficiently reduce postprandial blood glucose, fasting blood glucose and glycosylated haemoglobin Glimepiride tablets monotherapy can comprehensively reduce FPG PPG and HbA1c in newly diagnosed T2DM patients Combination therapy, such as combined metformin, acarbose, etc., has a more significant overall hypoglycemic effect Less hypoglycemia, less weight impact, high safety Short-term treatment, the risk of glimepiride hypoglycemia is only 1/3 of that of Glibenclamide Long-term treatment, the risk of glimepiride hypoglycemia is only 1/7of that of Glibenclamide Glimepiride has a small impact on the weight of T2DM patients Once a day to improve patient compliance If the patient's compliance is poor, Glimepiride tablets should be selected, once a day.

#glimepiride #package #insert

Since Gadopentetate Dimeglumine Injection was launched in 1992 by Beilu Pharma in China, it was highly recommended and accepted by the radiologist, and quickly occupied the market with its excellent quality and reasonable price. Up to now, linear gadolinium has been safely used for nearly 30 years, with excellent enhancement effects and few side effects. Product name: Gadopentetate Dimeglumine Injection Generic name: Gadopentetate Dimeglumine Injection Type: Injectable Contrast Media for MRI, Linear Contrast Media No.1 market share in China Ingredients: Gadopentetate Dimeglumine Specification: 10ml:4.69 g; 12ml:5.63 g; 15ml:7.04 g; 20ml:9.38 g Posology and method of administration: Intravenous injection Adverse reactions: See the details from the package insert Shelf life: 36 months Indication of Gadopentetate Dimeglumine Injection Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues. Precautions of Gadopentetate Dimeglumine Injection 1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies. 2. Take care to avoid the extravasation of the gadopentetic acid liquid during injection to prevent tissue pain. 3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours. 4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk. 5. The effective enhancement time of Magnevist contrast is 45 minutes. MRI examination should be performed immediately after intravenous injection. 6. The remaining medicine liquid after one examination should not be used again. 7. When applying this type of MRI contrast media, follow the relevant safety regulations in magnetic resonance imaging. 8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible. 9. Gadolinium deposition Current evidence shows that after repeated use of GBCAs, trace amounts of gadolinium can remain in the brain and other body tissues. Research reports have shown that multiple uses of GBCAs can increase the intensity of brain signals, especially in the dentate nucleus and globus pallidus. Currently, there are more reports about linear GBCAs and fewer reports about macrocyclic GBCAs. Animal experiments have shown that the amount of gadolinium deposited after repeated use of linear GBCAs is higher than that of repeated use of macrocyclic. The clinical significance of brain gadolinium deposition is unclear. In order to minimize the potential risks associated with gadolinium deposition in the brain, it must be used in strict accordance with the indications and approved doses. It is recommended to use the lowest approved dose that meets the requirement of diagnosis and perform a careful benefit-risk assessment and patient informed communication before repeated administration.

#Gadopentetate #Dimeglumine #Injection

The main component of CT/X-ray Contrast Media is iodine. The Iodinated Contrast Media is a colorless, transparent, slightly viscous liquid. At present, the CT contrast agents can be mainly divided into ionic and non-ionic, according to the osmotic pressure can be divided into hypertonic, isotonic and hypotonic. Currently, non-ionic, isotonic or hypotonic Contrast Media are used clinically. When the CT contrast medium is injected, 97% of the contrast media products can be directly excreted from the kidneys within 1 day. CT/X-Ray Contrast Media Types of Contrast Media in CT/X-ray Iohexol Injection Iohexol Injection is non-ionic contrast agent. Compared with traditional ionic contrast agent, Iohexol Injection has the excellent molecular structure, it has greatly improved safety, and significantl... Iopamidol Injection Iopamidol Injection is the second-generation non-ionic iodinated contrast media launched in the global market. In 2015, Beilu firstly launched and listed this product in the Chinese market. Product name: Iopam... Iodixanol Injection Iodixanol Injection is a Contrast Media that is isotonic with plasma. It has excellent cardiac safety and renal safety, which is most comfortable to use, especially suitable for high risk patients. Reasonable Use of Iodinated Contrast Agents Evaluate patient benefits/risks before use History of allergies: Patients who have previously experienced moderate to severe anaphylactoid reactions to iodinated contrast agents or patients with a history of allergies requiring treatment are at an increased risk of having an allergic reaction to CT scan contrast dye. Kidney function: iodinated contrast agents can cause acute kidney injury, and patients should be evaluated for related risks before the surgery. Combination medication: drugs that may increase the risk of adverse reactions to iodinated contrast agents: neuroleptics and antidepressants, interleukin-2, beta-blockers, metformin. Situations where iodinated contrast agents should be used with caution: lung and heart diseases, catecholamine secreting tumours, pregnant and lactating women, myeloma and macroglobulinemia, myasthenia gravis, homocystinuria. Contraindication: uncured patients with hyperthyroidism. Dose limit for iodinated contrast agents On the premise of satisfying imaging/diagnosis, the minimum dose of iodinated contrast agents should be used. For low-risk patients, the total dose of types of contrast agents had better be controlled within 300 ~ 400 ml. Maximum dose of iodinated radiocontrast dye Method I *: 5 ml × body weight (kg)/serum creatinine (mg/dl) (not more than 300 ml) [refer to Cigarroa calculation formula] Method II: 3.7 times creatinine clearance [according to 2011 ACCF/AHAUA/NSTEMI Treatment Guidelines] For those with severe renal insufficiency, try to choose an imaging method that does not require iodine-based contrast agents or a non-imaging method that can provide sufficient diagnostic information. Avoid repeated use of the diagnostic dose of an iodinated contrast medium in a short period of time. If repeated use is indeed necessary, it is recommended that the interval between two MRI contrast agent applications be ≥14 days. Other precautions for the use of iodinated contrast agents Preheating: Before using an iodinated contrast agent, it is recommended to heat the contrast agent to 37 °C and place it in a thermostat. Hydration: It is recommended to hydrate patients within 6 to 12 hours before using an iodinated contrast agent to within 24 hours after use. Hydration method: Intra-arterial drug users are advised to receive intravenous rehydration and oral rehydration concomitantly, and oral rehydration is recommended for intravenous drug users. Stay and observation: After the injection of the iodine-based contrast media, the patient needs to stay and be observed for 30 minutes before leaving the examination room. Establish an emergency channel: Establish an emergency rapid support mechanism for the rescue of adverse reactions caused by iodinated contrast agents with the emergency room or other clinical related departments to ensure that after an adverse reaction occurs, clinicians can promptly rush to the rescue scene for rescue if necessary. Prevention and Management of Vascular Extravasation of Iodinated Contrast Agents Prevention Choose appropriate blood vessels for venipuncture and operate carefully; when using a high-pressure syringe, choose a puncture needle and catheter that match the injection flow rate; properly fix the puncture needle; communicate with the patient and get cooperation. Management Mild extravasation: Most injuries are minor and need no treatment. However, the patient should be instructed to keep observing. If the extravasation worsens, the patient should seek medical attention in time. For individuals with significant pain, common cold and hydropathic compresses can be given locally. Moderate and severe extravasation: ① raise the affected limb to promote blood return. ② Use 50% magnesium sulfate moisturizing cold compress in the beginning, and after 24-hours change to magnesium sulfate moisturizing hot compress, or use mucopolysaccharide ointment for topical application, or use 0.05% dexamethasone for local hydropathic compress. ③ Those with severe contrast agent extravasation should be given oral dexamethasone 5 mg/time tid for 3 consecutive days on the basis of topical drug use. ④ If necessary, consult a clinician for medication.

#glimepiride #and #contrast #dye

Contrast Media Manufacturing Company For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of local tissues of the body. This introduced substance is Contrast Media, also known as Contrast Agents. As the first Contrast Media manufacturer in China, Beilu Pharma, as one of the most professional contrast media companies, launched the domestic MRI Contrast Media Gadopentetate Dimeglumine Injection in 1992, which broke the foreign products monopoly and filled the domestic gap. As a well-known contrast media company, we could provide a broad portfolio stems Contrast Media across CT/X-ray and MRI modalities, and own the EU standard manufacturing facilities. Types of Contrast Media in Beilu Pharma MRI CONTRAST MEDIA Magnetic Resonance Imaging (MRI)Contrast Media is Gadolinium based contrast agent(GBCA). It is an intravenous injection, mainly used to enhance the image quality of internal organs, blood vessels and tissues during MRI examinations. GBCA contains gadolinium, which is connected to each other through carrier molecules to form a chelating agent. According to the different chemical structures, this contrast medium can be divided into two categories: linear and macrocyclic. The linear structure of the imaging agents is easier to release gadolinium ions, and the macrocyclic structure of the contrast material is more stable and less likely to release gadolinium ions. CT/X-RAY CONTRAST MEDIA Iodine-containing Contrast Media is one of the common imaging contrast agents used in radiology diagnosis and interventional therapy. It is also a basic diagnosis drug for cardiovascular imaging under X-ray. Currently, the iodinated Contrast Media used for cardiovascular system CT and digital subtraction angiography are all water-soluble organic iodinated contrast materials. Finished Types of Contrast Media S. No Product name Characteristic Specification 1 Gadopentetate Dimeglumine Injection Injectable solution 469mg/ml: 10ml, 12ml, 15ml, 20ml 2 Gadobutrol Injection Injectable solution 604.72mg/ml: 7.5ml 3 Ammonium iron citrate Oral granules 3g：0.6g（Fe 129mg） 6g：1.2g（Fe 258mg） 4 Iopamidol Injection Injectable solution 300mgI/ml: 50ml, 100ml 370mgI/ml: 50ml, 100ml 5 Iodixanol Injection Injectable solution 270mgI/ml: 100ml 320mgI/ml: 50ml, 100ml 6 Iohexol Injection Injectable solution 300mgI/ml: 20ml,50ml,75ml, 100ml 350mgI/ml: 20ml, 50ml, 100ml API & Intermediates Types of Contrast Media S. No Products CAS NO. Packings Classification 1 Iohexol 66108-95-0 25kg Contrast agent 2 Iodixanol 92339-11-2 25kg Contrast agent 3 Iopromide 73334-07-3 25kg Contrast agent 4 Iopamidol 60166-93-0 25kg Contrast agent 5 Ioversol 87771-40-2 25kg Contrast agent 6 Gadopentetate Monomeglumine 92923-57-4 25kg Contrast agent 7 Gadopentetate Dimeglumine 86050-77-3 25kg Contrast agent 8 Gadobutrol 138071-82-6 25kg Contrast agent 9 Calcobutrol 151878-23-8 2kg Excipients 10 Repaglinide 135062-02-1 10kg Anti-diabetic 11 Diethylenetriaminepentaacetic acid ( Pentaacetic Acid)（DTPA） 67-43-6 2.5kg Intermediates 12 Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid 35453-19-1 25kg Intermediates Comparison of physicochemical characteristics of commonly used Contrast Media Contrast media Osmotic pressure Viscosity (Concentration：mg（I）/ml) (mOsm/kg water）（cP，37℃） Iopamidol 300 616 4.7 Ioverol 300 651 5.5 Iohexol 300 672 6.3 Iobitridol 300 695 6 Iodixanol 320 290 11.8 The osmotic pressure of normal people is about 290-300mOsm/kg. Taking the viscosity of water as 1, when the temperature is 37℃, the relative viscosity of whole blood is 4-5, and the relative viscosity of plasma is 1.6-2.4. Three factors of renal injury induced by Contrast Media: Osmotic pressure, Viscosity and the total iodine. Reduced iodine intake is a feasible strategy to avoid kidney damage.

#contrast #media #suppliers

CAS No.: 151878-23-8 Molecular formula: C18H32CaN4O9 Molecular weight: 488.5461 Quality standard: CP Characteristics: White or off-white powder Content (HPLC): ≥99.0% Packing: 2KG/ drum Storage: Protected from light, sealed tightly.

#calcobutrol

Iodixanol Injection

Iodixanol Injection is a Contrast Media that is isotonic with plasma. It has excellent cardiac safety and renal safety, which is most comfortable to use, especially suitable for high risk patients.

Product name: Iodixanol Injection

Generic name: Iodixanol Injection

Type: Injectable Contrast media for CT/X-ray

Ingredients: Iodixanol

Specification:

(1) 50ml: 16 gI

(2) 100 ml: 32 gI

(3) 100 ml: 27 gI

Administration: For Intravascular use only

Adverse reactions: See the details from the package insert

Shelf life: 24 months

Indications of Iodixanol Injection

The iodixanol visipaque contrast media is mainly used for adult angiocardiography, cerebral angiography, peripheral arteriography, abdominal angiography, Urography, venography and enhanced CT scan, children angiocardiography, urography and enhanced CT scan.

For more precautions, please refer to the package insert.

http://beilupharma.com/products/iodixanol-injection.html

#visipaque #contrast #media

Glimepiride Tablets

Product name: Glimepiride Tablets

Specifications: glimepiride 1 mg×30 tablets；glimepiride 2 mg×15 tablets；glimepiride 2mg×30 tablets

Characteristics: White tablet

Indications :

As one of the oral antidiabetic drugs produced by Beilu Pharma, our glimepiride tablets are only suitable for type 2 diabetes that cannot fully control blood sugar through diet control, exercise therapy and weight loss.

Glimepiride tablets are not suitable for type 1 diabetes (for example, the treatment of diabetic patients with a history of ketoacidosis), diabetic ketoacidosis or Treatment of pre-diabetic coma or coma.

Usage and Dosage: Please refer to the package insert

Adverse reactions, Contraindications, Precautions: Please refer to the package insert.

Storage: Shade, seal, and keep in a dry place.

Packaging: Aluminum plastic packaging, 15 pills/plate, 1 plate/box; 15 pills/plate, 2 plates/box.

Shelf life: 24 months

Advantages of Glimepiride Tablets

Double effect directly hit the hypoglycemic core

Double effect: Glimepiride tablets can promote insulin secretion and improve insulin resistance. At the same time, it can improve the two major pathophysiological abnormalities of insulin secretion and insulin resistance in patients with type 2 diabetes.

Efficiently reduce postprandial blood glucose, fasting blood glucose and glycosylated haemoglobin

Glimepiride tablets monotherapy can comprehensively reduce FPG PPG and HbA1c in newly diagnosed T2DM patients

Combination therapy, such as combined metformin, acarbose, etc., has a more significant overall hypoglycemic effect

Less hypoglycemia, less weight impact, high safety

Short-term treatment, the risk of glimepiride hypoglycemia is only 1/3 of that of Glibenclamide

Long-term treatment, the risk of glimepiride hypoglycemia is only 1/7of that of Glibenclamide

Glimepiride has a small impact on the weight of T2DM patients

Once a day to improve patient compliance

If the patient's compliance is poor, Glimepiride tablets should be selected, once a day.

http://beilupharma.com/products/glimepiride-tablets.html

#side #effects #of #glimepiride #1mg #tablet

Gadopentetate Dimeglumine Injection/API

Product name: Gadopentetate Dimeglumine Injection

Generic name: Gadopentetate Dimeglumine Injection

Type: Injectable Contrast Media for MRI, Linear Contrast Media

No.1 market share in China

Ingredients: Gadopentetate Dimeglumine

Specification: 10ml:4.69 g; 12ml:5.63 g; 15ml:7.04 g; 20ml:9.38 g

Posology and method of administration: Intravenous injection

Adverse reactions: See the details from the package insert

Shelf life: 36 months

Indication of Gadopentetate Dimegumine Injection

Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues.

Precautions of Gadopentetate Dimegumine Injection

1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies.

2. Take care to avoid the extravasation of the gadopentetic acid liquid during injection to prevent tissue pain.

3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours.

4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk.

5. The effective enhancement time of Magnevist contrast is 45 minutes. MRI examination should be performed immediately after intravenous injection.

6. The remaining medicine liquid after one examination should not be used again.

7. When applying this type of MRI contrast media, follow the relevant safety regulations in magnetic resonance imaging.

8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible.

9. Gadolinium deposition

Current evidence shows that after repeated use of GBCAs, trace amounts of gadolinium can remain in the brain and other body tissues. Research reports have shown that multiple uses of GBCAs can increase the intensity of brain signals, especially in the dentate nucleus and globus pallidus. Currently, there are more reports about linear GBCAs and fewer reports about macrocyclic GBCAs. Animal experiments have shown that the amount of gadolinium deposited after repeated use of linear GBCAs is higher than that of repeated use of macrocyclic.

The clinical significance of brain gadolinium deposition is unclear.

In order to minimize the potential risks associated with gadolinium deposition in the brain, it must be used in strict accordance with the indications and approved doses. It is recommended to use the lowest approved dose that meets the requirement of diagnosis and perform a careful benefit-risk assessment and patient informed communication before repeated administration.

http://beilupharma.com/products/gadopentetate-dimeglumine-injection-api/

#magnevist #price

Gadobutrol Injection/API

In 2020, Beilu launched its macrocyclic Contrast Media- Gadobutrol Injection, it is gadolinium-based non-ionic Contrast Media, a paramagnetic Contrast Media used in various parts of the body lesion (including the brain and spinal cord) MRI imaging and angiography examination. Its macrocyclic nature ensures it is well-tolerated with a good safety profile for MRI Contrast. As a professional contrast media manufacturer, Beilu can provide you with the high concentration gadobutrol gadovist that leads to a better image with lower volume.

Product name: Gadobutrol Injection

Generic name: Gadobutrol Injection

Type: Injectable Contrast Media for MRI, Macrocyclic Contrast Media

Ingredients: Gadobutrol

Specification: Gadovist 7.5 ml - 4.5354 g

Administration: Intravenous administration only.

Adverse reactions: See the details from the package insert.

Shelf life: 24 months

Indication of Gadopentetate Dimegumine Injection

Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues.

Precautions of Gadopentetate Dimegumine Injection

1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies.

2. Pay attention to avoid the extravasation of the liquid during the gadobutrol injection uses so as to prevent tissue pain.

3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours.

4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk.

5. The effective enhancement time of this product is 45 minutes. MRI examination should be performed immediately after intravenous injection.

6. The remaining medicine liquid after one examination should not be used again.

7. When applying the gadovist doses, follow the relevant safety regulations in magnetic resonance imaging.

8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible.

9. Gadolinium deposition

The clinical significance of brain gadolinium deposition is unclear.

http://beilupharma.com/products/gadobutrol-Injection-api.html

#gadobutrol #injection #uses

Ferric Ammonium Citrate Effervescent Granules

Ferric Ammonium Citrate Effervescent Granules was launched in 2004. It is an oral magnetic resonance contrast agent/media approved by NMPA in the market, which is a safe and effective double contrast agent with the advantages of convenient use and good safety. This ammonium iron citrate can significantly improve the images quality of MRCP and MRU, and can also be used as a positive contrast agent for the digestive tract.

Product name: Ferric Ammonium Citrate Effervescent Granules

Type: Oral MRI Contrast Media

Ingredients: Ferric ammonium citrate

Specification: 3g: 0.6g（Fe 129mg), 6g: 1.2g（Fe 258mg）

Posology and method of administration: Oral

Adverse reactions: Foreign clinical data reported that after using this MRI contrast medium, 0.1-0.5% of patients has diarrhea, 0.1% had nausea, vomiting, and decreased appetite, and a very small number of patients has stomach discomfort and bloating. All the above symptoms can be eliminated by themselves.

Shelf life: 24 months

Indications of Ferric Ammonium Citrate Effervescent Granules

Used for magnetic resonance abdominal imaging, angiography of the digestive tract (stomach duodenum and jejunum).

Precautions of Ferric Ammonium Citrate Effervescent Granules

Use with caution in the following patients: patients with the gastrointestinal tract such as peptic ulcer, ulcerative colitis, local enteritis, etc.

The stool appearing black after administration is a normal phenomenon.

During the ammonium citrate uses, false-positive for occult blood may occur.

http://beilupharma.com/products/ferric-ammonium-citrate-effervescent-granules.html

#mist #ferric #ammonium #citrate

CT/X-Ray Contrast Media

Reasonable Use of Iodinated Contrast Agents

Evaluate patient benefits/risks before use

History of allergies: Patients who have previously experienced moderate to severe anaphylactoid reactions to iodinated contrast agents or patients with a history of allergies requiring treatment are at an increased risk of having an allergic reaction to CT dye.

Kidney function: iodinated contrast agents can cause acute kidney injury, and patients should be evaluated for related risks before the surgery.

Combination medication: drugs that may increase the risk of adverse reactions to iodinated contrast agents: neuroleptics and antidepressants, interleukin-2, beta-blockers, metformin.

Situations where iodinated contrast agents should be used with caution: lung and heart diseases, catecholamine secreting tumours, pregnant and lactating women, myeloma and macroglobulinemia, myasthenia gravis, homocystinuria.

Contraindication: uncured patients with hyperthyroidism.

Dose limit for iodinated contrast agents

On the premise of satisfying imaging/diagnosis, the minimum dose of iodinated contrast agents should be used.

For low-risk patients, the total dose of types of contrast agents had better be controlled within 300 ~ 400 ml.

Maximum dose of iodinated radiocontrast dye

Method I *: 5 ml × body weight (kg)/serum creatinine (mg/dl) (not more than 300 ml) [refer to Cigarroa calculation formula]

Method II: 3.7 times creatinine clearance [according to 2011 ACCF/AHAUA/NSTEMI Treatment Guidelines]

For those with severe renal insufficiency, try to choose an imaging method that does not require iodine-based contrast agents or a non-imaging method that can provide sufficient diagnostic information.

Avoid repeated use of the diagnostic dose of an iodinated contrast agent in a short period of time. If repeated use is indeed necessary, it is recommended that the interval between two MRI contrast agent applications be ≥14 days.

Other precautions for the use of iodinated contrast agents

Preheating: Before using an iodinated contrast agent, it is recommended to heat the contrast agent to 37 °C and place it in a thermostat.

Hydration: It is recommended to hydrate patients within 6 to 12 hours before using an iodinated contrast agent to within 24 hours after use. Hydration method: Intra-arterial drug users are advised to receive intravenous rehydration and oral rehydration concomitantly, and oral rehydration is recommended for intravenous drug users.

Stay and observation: After the injection of the iodine-based contrast media, the patient needs to stay and be observed for 30 minutes before leaving the examination room.

Establish an emergency channel: Establish an emergency rapid support mechanism for the rescue of adverse reactions caused by iodinated contrast agents with the emergency room or other clinical related departments to ensure that after an adverse reaction occurs, clinicians can promptly rush to the rescue scene for rescue if necessary.

Prevention and Management of Vascular Extravasation of Iodinated Contrast Agents

Prevention

Choose appropriate blood vessels for venipuncture and operate carefully; when using a high-pressure syringe, choose a puncture needle and catheter that match the injection flow rate; properly fix the puncture needle; communicate with the patient and get cooperation.

Management

Mild extravasation: Most injuries are minor and need no treatment. However, the patient should be instructed to keep observing. If the extravasation worsens, the patient should seek medical attention in time. For individuals with significant pain, common cold and hydropathic compresses can be given locally.

Moderate and severe extravasation: ① raise the affected limb to promote blood return. ② Use 50% magnesium sulfate moisturizing cold compress in the beginning, and after 24-hours change to magnesium sulfate moisturizing hot compress, or use mucopolysaccharide ointment for topical application, or use 0.05% dexamethasone for local hydropathic compress. ③ Those with severe contrast agent extravasation should be given oral dexamethasone 5 mg/time tid for 3 consecutive days on the basis of topical drug use. ④ If necessary, consult a clinician for medication.

http://beilupharma.com/products/ct-x-ray-contrast-media/

#iodine #based #contrast #agents

Contrast Media

For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of local tissues of the body. This introduced substance is Contrast Media, also known as Contrast Agents. As the first Contrast Media manufacturer in China, Beilu Pharma launched the domestic MRI Contrast Media Gadopentetate Dimeglumine Injection in 1992, which broke the foreign products monopoly and filled the domestic gap. As a professional contrast media manufacturer, we could provide a broad portfolio stems Contrast Media across CT/X-ray and MRI modalities, and own the EU standard manufacturing facilities.

Types of Contrast Media in Beilu Pharma

Magnetic Resonance Imaging (MRI)Contrast Media is Gadolinium based contrast agent(GBCA). It is an intravenous injection, mainly used to enhance the image quality of internal organs, blood vessels and tissues during MRI examinations. GBCA contains gadolinium, which is connected to each other through carrier molecules to form a chelating agent. According to the different chemical structures, this contrast medium can be divided into two categories: linear and macrocyclic. The linear structure of the imaging agents is easier to release gadolinium ions, and the macrocyclic structure of the contrast material is more stable and less likely to release gadolinium ions.

http://beilupharma.com/products/contrast-media/

#imaging #agents

Anti-Diabetic Drugs

The number of people with diabetes rose from 151 million in 2000 to 463 million in 2019; by 2045 this number will rise to 700 million. 1 in 5 of the people who are above 65 years old have diabetes, 1 in 2 people (232 million) with diabetes were undiagnosed, and diabetes caused 4.2 million deaths. Diabetes caused at least USD760 billion dollars in health expenditure in 2019 – 10% of total spending on adults. More than 1.1 million children and adolescents are living with type 1 diabetes, and 374 million people are at increased risk of developing type 2 diabetes.

Diabetes is a chronic disease. Diabetes occurs when the pancreas cannot produce enough insulin or the body cannot effectively use the produced insulin (diabetes is a hormone that regulates blood sugar). High blood sugar or elevated blood sugar is a common result of uncontrolled diabetes. Over time, diabetes can seriously damage many systems of the human body, especially nerves and blood vessels, so the prevention and treatment of diabetes is particularly important in our daily life. In fact, the incidence of diabetes in low- and middle-income countries is rising faster than in high-income countries. As the health problems of diabetes threaten people's lives seriously, the prevention of diabetes and the corresponding antidiabetic medications have also attracted more and more attention. As a professional anti-insulin drugs manufacturer, Beilu Pharma can provide you with 2 different types of high-quality oral antidiabetic drugs.

http://beilupharma.com/products/anti-diabetic-drugs/

#antidiabetic #brand #names

Trending Blogs

Recently Viewed Blogs

beilupharma